Avoro Capital Advisors Reduces $218M in Amicus Therapeutics Inc ($FOLD)

Avoro Capital Advisors has completely sold its position in FOLD, according to its latest Form 13F filing with the SEC. The filing, dated February 17, 2026, shows that Avoro Capital Advisors divested its entire holding of 15.03 million shares, marking a 100% reduction.

What Changed in Avoro Capital Advisors' FOLD Position

Avoro Capital Advisors had previously held 15.03 million shares of FOLD. The recent filing indicates that the firm has sold all of its shares, resulting in a complete exit from its investment in the company.

Other Institutional Activity in FOLD

Other institutional investors have made significant moves in FOLD as well. BlackRock, Inc. increased its holdings by 1,354,667 shares, bringing its total to 33.88 million shares, valued at approximately $489.9 million. UBS Group AG significantly increased its position by 10,064,625 shares, reaching a total of 15.96 million shares worth about $230.8 million. Meanwhile, Vanguard Capital Management LLC added 14.02 million shares, now holding shares valued at $202.8 million. Pentwater Capital Management LP boosted its stake by 2.5 million shares, totaling 14 million shares, worth around $202.4 million. Conversely, State Street Corp reduced its position by 1,939,417 shares, bringing its total down to 12.89 million shares, valued at $186.4 million.

FOLD Stock Snapshot

Shares of FOLD traded at $14.49. The stock has seen various institutional adjustments recently, reflecting different strategic positions by major funds.

Insider Buying and Selling at Amicus Therapeutics Inc

Several insiders at FOLD sold shares recently. On April 27, 2026, President and CEO Bradley Campbell sold 1,008,680 shares at an average price of $14.50. Other insiders, including Ellen Rosenberg, the Chief Legal Officer, and Chief People Officer David Michael Clark, also sold shares on the same date.

Analysts Set New Price Targets

Analysts have adjusted their outlook on FOLD. On January 22, 2026, Jefferies downgraded FOLD to a 'hold' rating with a price target of $14.5. Similarly, Citigroup and Leerink Partners also downgraded the stock to 'hold' with the same price target in late December 2025.

About FOLD

FOLD operates in the healthcare sector, focusing on developing therapies for rare diseases. The company is involved in research and development to provide innovative solutions for unmet medical needs. With a global presence, FOLD is committed to advancing healthcare through its specialized products.

Bottom Line

Avoro Capital Advisors' exit from FOLD is a significant move, reflecting a complete shift in their investment strategy. Investors keep a close eye on such filings to gauge fund sentiment, although these 13F reports are backward-looking and may not reflect current positions. Institutional activity and analyst ratings provide additional context for FOLD's market position.